Close Menu

NEW YORK (360Dx) – OraSure Technologies reported after the close of the market on Wednesday that its fourth quarter revenues dipped 1 percent year over year.

For the three months ended Dec. 31, 2019, the point-of-care diagnostic testing and specimen collection device manufacturer reported revenues of $49.7 million, down from $50.2 million a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.